Michael McManus
Child & Adolescent Psychiatry · San Diego, CANPI 1669411179
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Supernus Pharmaceuticals, Inc. accounts for 68.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $9,885 and has fallen 98.6% since, to $141 in 2025. Among child & adolescent psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $42.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$10K
- Sunovion Pharmaceuticals Inc.$1K
- AbbVie$968
- Hoffmann-la Roche Limited$555
- Neurocrine Biosciences, Inc.$300
- Vanda Pharmaceuticals Inc.$197
- plus $1K from 15 others
Across 231 payments — averaging $1782.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$135K
- Genentech, Inc.$135K
- F. Hoffmann-la Roche AG$45K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$27K
- Sunovion Pharmaceuticals Inc.$23K
- Hoffmann-la Roche Limited$16K
- plus $31K from 5 others
What the payments were for
- Consulting fees$5554%
- Speaking & faculty fees$8,90060%
- Food & beverage$5,37336%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 69 | $10,189 |
| Sunovion Pharmaceuticals Inc. | 132 | $1,328 |
| AbbVie(2 entities) | 57 | $968 |
| Hoffmann-la Roche Limited | 2 | $555 |
| Neurocrine Biosciences, Inc. | 14 | $300 |
| Vanda Pharmaceuticals Inc. | 7 | $197 |
| Ironshore Pharmaceuticals Inc. | 11 | $194 |
| Teva Pharmaceuticals USA, Inc. | 9 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $184 |
| Shire North American Group Inc | 9 | $155 |
| Alkermes, Inc. | 7 | $143 |
| Johnson & Johnson | 4 | $112 |
| Lundbeck LLC | 3 | $68 |
| Vertical Pharmaceuticals, LLC | 3 | $61 |
| Corium, LLC | 3 | $46 |
| Tris Pharma Inc | 2 | $44 |
| Bausch Health US, LLC | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$6,299
- Non-Covered Product$555
How this compares
$14,870 in reported general payments places this provider in the 95th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 41 | $348,097 |
| VraylarCariprazine Hcl | 103 | $177,419 |
| CaplytaLumateperone Tosylate | 31 | $51,493 |
| Aripiprazole | 246 | $42,115 |
| Lurasidone Hcl | 199 | $29,054 |
| Quetiapine Fumarate | 697 | $14,815 |
| Olanzapine | 605 | $14,394 |
| TrintellixVortioxetine Hydrobromide | 27 | $12,702 |
| Risperidone | 475 | $6,145 |
| Chlorpromazine Hcl | 40 | $5,766 |
| Divalproex Sodium | 175 | $5,015 |
| Haloperidol | 79 | $4,927 |
| Clozapine | 56 | $4,306 |
| Fluoxetine Hcl | 286 | $4,190 |
| Oxcarbazepine | 96 | $4,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $300 | $348,09741 claims |
| AbbVieVraylar | $968 | $177,419103 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $184 | $12,70227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 child & adolescent psychiatry providers in California.
Other child & adolescent psychiatry in San Diego
- Ellen HeynemanSan Diego$62K
- Michael KornbergSan Diego$7K
- Kevin CoxOjai$2.9M
- Sukhjit BrarFresno$283K
- Manpreet SinghSacramento$104K
- Ihab SolimanCorona del Mar$93K
- Syed NaqviLos Angeles$69K
- Mark McDonaldLos Angeles$31K
- James HartmanDanville$21K
- Mohsin KhaliqueSan Ramon$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.